Study of Cetuximab in Combination With Carboplatin-Paclitaxel in Non-Small Cell Lung Cancer

Phase 1/2 Completed 32 enrolled Eli Lilly and Company Greenwich Hospital · collab Indiana University · collab University of Colorado, Denver · collab

Non-randomizedSingle-groupOpen-labelTreatment

Summary

The study will enroll approximately 33 EGFr positive chemotherapy-naive stage IV non-small cell lung cancer patients. Patients will receive cetuximab in combination with carboplatin and paclitaxel for two cycles or until disease progression or until the patient exhibits intolerable toxicities. Patients will be evaluated for efficacy and safety throughout the duration of the study.

Timeline

Start: 2000-12
Primary completion: 2003-05
Completion: 2003-05

Publications

Results Thienelt CD, Bunn PA Jr, Hanna N, Rosenberg A, Needle MN, Long ME, Gustafson DL, Kelly K. Multicenter phase I/II study of cetuximab with paclitaxel and carboplatin in untreated patients with stage IV non-small-cell lung cancer. J Clin Oncol. 2005 Dec 1;23(34):8786-93. doi: 10.1200/JCO.2005.03.1997. Epub 2005 Oct 24.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Carboplatin	Small molecule	6 unknown	—
Subject	Cetuximab	Monoclonal antibody	250 mg/m2	Intravenous
Subject	Paclitaxel	Small molecule	225 mg/m2	—

Study of Cetuximab in Combination With Carboplatin-Paclitaxel in Non-Small Cell Lung Cancer

Summary

Timeline

Publications

Drugs

Indications